MedTrace Logo

Evaluation of Community-based Mass Screening and Treatment for Malaria in Western Kenya

NCT02987270 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90000

Last updated 2016-12-09

No results posted yet for this study

Summary

This study is a cluster-randomized controlled trial to evaluate the efficacy of community-based mass screening with a malaria rapid diagnostic test, and treatment of participants with positive tests with an appropriate antimalarial for reducing malaria transmission indices.

Conditions

  • Malaria,Falciparum

Interventions

DRUG

Dihydroartemisinin-piperaquine

Dihydroartemisinin-piperaquine is an antimalarial in the artemisinin-based combination therapy class of drugs. It is the Kenya Ministry of Health second-line treatment for malaria in Kenya.

Sponsors & Collaborators

Principal Investigators

  • Meghna R Desai, PhD · Centers for Disease Control and Prevention

  • Simon K Kariuki, PhD · Kenya Medical Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2015-08-31
Completion
2015-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02987270 on ClinicalTrials.gov